Juli R. Bago

Juli R. Bago

Ostravská univerzita

H-index: 22

Europe-Czech Republic

About Juli R. Bago

Juli R. Bago, With an exceptional h-index of 22 and a recent h-index of 15 (since 2020), a distinguished researcher at Ostravská univerzita, specializes in the field of Cancer Research, Tissue Regeneration, Cell-Based Therapy.

His recent articles reflect a diverse array of research interests and contributions to the field:

Novel Local “Off-the-Shelf” Immunotherapy for the Treatment of Myeloma Bone Disease

NK92 Expressing Anti-BCMA CAR and Secreted TRAIL for the Treatment of Multiple Myeloma: Preliminary In Vitro Assessment

Cell competition for cancer treatment with Urine Progenitor Cells

NK92 Expressing anti-BCMA CAR and Secreted TRAIL: a Promising Combination Treatment against Multiple Myeloma

Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility

Preclinical scenario of targeting myocardial fibrosis with chimeric antigen receptor (CAR) immunotherapy

Anti-BCMA-CAR NK cells expressing soluble TRAIL: promising therapeutic approach for multiple myeloma in combination with bortezomib and γ-secretase inhibitors

Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine

Juli R. Bago Information

University

Position

Principal Investigator at

Citations(all)

1804

Citations(since 2020)

935

Cited By

1205

hIndex(all)

22

hIndex(since 2020)

15

i10Index(all)

25

i10Index(since 2020)

21

Email

University Profile Page

Ostravská univerzita

Google Scholar

View Google Scholar Profile

Juli R. Bago Skills & Research Interests

Cancer Research

Tissue Regeneration

Cell-Based Therapy

Top articles of Juli R. Bago

Title

Journal

Author(s)

Publication Date

Novel Local “Off-the-Shelf” Immunotherapy for the Treatment of Myeloma Bone Disease

Cells

Sandra Charvátová

Benjamin Motais

Justyna Czapla

Tomasz Cichoń

Ryszard Smolarczyk

...

2023/1/30

NK92 Expressing Anti-BCMA CAR and Secreted TRAIL for the Treatment of Multiple Myeloma: Preliminary In Vitro Assessment

Cells

Benjamin Motais

Sandra Charvátová

Zuzana Walek

Roman Hájek

Juli R Bagó

2023/11/30

Cell competition for cancer treatment with Urine Progenitor Cells

bioRxiv

Juli R Bago

Dhwani Radhakrishnan

Matous Hrdinka

Tomasz Cichon

Ryszard Smolarczyk

...

2023

NK92 Expressing anti-BCMA CAR and Secreted TRAIL: a Promising Combination Treatment against Multiple Myeloma

Benjamin Motais

Sandra Charvatova

Zuzana Walek

Roman Hajek

Juli Bagó

2023/8/23

Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility

Piotr Celichowski

Marcello Turi

Sandra Charvátová

Dhwani Radhakrishnan

Neda Feizi

...

2023/3/15

Preclinical scenario of targeting myocardial fibrosis with chimeric antigen receptor (CAR) immunotherapy

Gemma Ferrer-Curriu

Carolina Soler-Botija

Sandra Charvatova

Benjamin Motais

Santiago Roura

...

2023/2/1

Anti-BCMA-CAR NK cells expressing soluble TRAIL: promising therapeutic approach for multiple myeloma in combination with bortezomib and γ-secretase inhibitors

Blood

Benjamin Motais

Sandra Charvátová

Matouš Hrdinka

Roman Hájek

Juli R Bago

2022/11/15

Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine

Blood Advances

Martina Zátopková

Tereza Ševčíková

Viola Fanfani

Zuzana Chyra

Lucie Říhová

...

2022/1/25

Developing bioinspired three-dimensional models of brain cancer to evaluate tumor-homing neural stem cell therapy

Tissue Engineering Part A

Abigail G Carey-Ewend

Shaye B Hagler

Hunter N Bomba

Morgan J Goetz

Juli R Bago

...

2021/7/1

Development of next-generation tumor-homing induced neural stem cells to enhance treatment of metastatic cancers

Science Advances

Wulin Jiang

Yuchen Yang

Alison R Mercer-Smith

Alain Valdivia

Juli R Bago

...

2021/6/9

Delivery vehicles for stem cells and uses thereof

2021/6/8

Selection, expansion, and unique pretreatment of allogeneic human natural killer cells with anti-Cd38 monoclonal antibody for efficient multiple myeloma treatment

Cells

Benjamin Motais

Sandra Charvátová

Zuzana Walek

Matouš Hrdinka

Ryszard Smolarczyk

...

2021/4/21

Pathogenesis of Extramedullary Multiple Myeloma: From Resistance to Identification of Novel Therapeutic Targets

Blood

Tomas Jelinek

David Zihala

Tereza Sevcikova

Veronika Kapustova

Hana Sahinbegovic

...

2021/11/23

Cytotoxic Engineered Induced Neural Stem Cells as an Intravenous Therapy for Primary Non–Small Cell Lung Cancer and Triple-Negative Breast Cancer

Molecular cancer therapeutics

Alison R Mercer-Smith

Wulin Jiang

Juli R Bago

Alain Valdivia

Morrent Thang

...

2021/11/1

Generation and profiling of tumor-homing induced neural stem cells from the skin of cancer patients

Molecular Therapy

Andrew Buckley

Shaye B Hagler

Vivien Lettry

Juli R Bagó

Spencer M Maingi

...

2020/7/8

Identification of Molecular Mechanisms Responsible for the Development of Extramedullary Disease in Myeloma and Potential Novel Therapeutic Targets Using Transcriptomic and …

Blood

David Zihala

Tereza Sevcikova

Michal Simicek

Tereza Popkova

Hana Plonkova

...

2020/11/5

Intercellular mitochondrial transfer in the tumor microenvironment

Hana Sahinbegovic

Tomas Jelinek

Matous Hrdinka

Juli R Bago

Marcello Turi

...

2020/7/4

EXTH-11. PATIENT DERIVED INDUCED NEURAL STEM CELLS FOR TREATMENT OF GLIOBLASTOMA

Neuro-oncology

GLIOBLASTOMA PATIENT DERIVED XENOGRAFTS

2020/11

A Bird’s-Eye View of Cell Sources for Cell-Based Therapies in Blood Cancers

Benjamin Motais

Sandra Charvátová

Matouš Hrdinka

Michal Šimíček

Tomáš Jelínek

...

2020/5/23

EXTH-24. INCREASING THERAPEUTIC INDUCED NEURAL STEM CELL PERSISTENCE IN THE GLIOBLASTOMA TUMOR RESECTION CAVITY

Neuro-Oncology

Hunter Bomba

Kevin Sheets

Abigial Carey-Ewend

Morgan Goetz

Ingrid Findlay

...

2020/11

See List of Professors in Juli R. Bago University(Ostravská univerzita)